bazedoxifene has been researched along with Fractures, Bone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, Z; Hu, Q; Ma, Y; Ren, L | 1 |
| Arias, L; Bueno, JAH; Komm, BS; Williams, R; Yu, CR | 1 |
| Adami, S; Chines, AA; Levine, AB; Palacios, S; Rizzoli, R; Sutradhar, S | 1 |
| Chines, AA; Constantine, GD; Gorai, I; Itabashi, A; Miki, T; Mizunuma, H; Ochi, H; Ohta, H; Sato, H; Sugimoto, T; Takada, M; Yoh, K | 1 |
| Cappelleri, JC; Chines, A; Ellis, AG; Jansen, JP; Luo, X; Reginster, JY; Sutradhar, S | 1 |
| Brown, JP; Chines, AA; De Cicco Nardone, F; de Villiers, TJ; Goemaere, S; Hines, TL; Levine, AB; Mirkin, S; Palacios, S; Silverman, SL; Williams, R | 1 |
| Chines, AA; Christiansen, C; Constantine, GD; de Villiers, TJ; Genant, HK; Silverman, SL; Vukicevic, S; Zanchetta, JR | 1 |
| Fukawa, T; Kamiya, S; Wada, S | 1 |
| Johansson, H; Kanis, JA; McCloskey, EV; Oden, A | 1 |
| de Villiers, TJ | 1 |
| Borgström, F; Johansson, H; Kanis, JA; Kleman, M; McCloskey, E; Odén, A; Ström, O | 1 |
| Schmidt, C | 1 |
| Ohta, H | 1 |
| Chines, AA; Komm, BS | 1 |
| Duggan, ST; Keating, GM; Lyseng-Williamson, KA; McKeage, K | 1 |
| Hadji, P | 1 |
6 review(s) available for bazedoxifene and Fractures, Bone
| Article | Year |
|---|---|
Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal | 2014 |
[Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
Topics: Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Design; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Indoles; Organometallic Compounds; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Zoledronic Acid | 2008 |
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Endometrium; Female; Fractures, Bone; Humans; Indoles; Lipids; Mammography; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Ultrasonography; Venous Thromboembolism | 2010 |
[Bazedoxifene as a new-generation SERM].
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators | 2011 |
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
7 trial(s) available for bazedoxifene and Fractures, Bone
| Article | Year |
|---|---|
Bazedoxifene effects on osteoprotegerin, insulin-like growth factor, tumor necrosis factor and bone mineral density.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Indoles; Insulin-Like Growth Factor I; Lumbar Vertebrae; Middle Aged; Orthotic Devices; Osteoprotegerin; Tumor Necrosis Factor-alpha | 2020 |
Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis.
Topics: Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Latin America; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Placebos; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures | 2017 |
The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause | 2014 |
Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Cohort Studies; Double-Blind Method; Female; Fracture Healing; Fractures, Bone; Humans; Indoles; Japan; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Safety; Postmenopause | 2015 |
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Indoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Time; Treatment Outcome | 2015 |
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Female; Fractures, Bone; Humans; Indoles; Lumbar Vertebrae; Middle Aged; Osteoporosis; Placebos; Postmenopause; Selective Estrogen Receptor Modulators; Time Factors; Treatment Outcome | 2008 |
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Risk Factors; Spinal Fractures | 2009 |
3 other study(ies) available for bazedoxifene and Fractures, Bone
| Article | Year |
|---|---|
FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.
Topics: Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Fractures, Bone; Health Care Costs; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Risk Assessment; Sweden | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
Bazedoxifene: a guide to its use in postmenopausal osteoporosis.
Topics: Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal | 2012 |